
zzso is known to penetrate the zzso barrier and sensitize brain tumors to radiation and has been used clinically to sensitize zzso external beam zzso However, there are limited prospective clinical data available on the safety of zzso as a zzso agent administered with zzso zzso This is a phase I trial of previously zzso patients with one to four progressive brain zzso and zzso performance scale score zzso % enrolled in three sequential zzso zzso 100, 150 or 200 zzso day) administered for 5 zzso zzso zzso zzso was administered on day zzso The zzso dose was dependent on target zzso 15 zzso zzso zzso 18 zzso zzso zzso or 21 zzso zzso zzso The primary zzso was safety of increasing zzso zzso Secondary zzso included local control and zzso 26 subjects were enrolled and 49 total zzso zzso were zzso The median number of brain zzso was zzso with a median target diameter of 21 zzso The most common grade 1-2 adverse events irrespective of causality were vomiting zzso zzso zzso zzso zzso zzso (12 zzso seizure (8 zzso psychosis (4 zzso and zzso (4 zzso The frequency of zzso and vomiting did not appear to be zzso Grade zzso zzso were not zzso Median overall survival was zzso zzso Crude local control was zzso zzso with a zzso response seen in eight of 24 zzso patients zzso zzso and stable disease zzso months in 13 of 24 patients zzso zzso zzso at doses up to 200 zzso day) zzso 5 days, prior to zzso is well zzso with no zzso zzso in patients with zzso brain zzso Local control of target zzso was zzso zzso 

